1. Home
  2. ZLAB vs TFIN Comparison

ZLAB vs TFIN Comparison

Compare ZLAB & TFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • TFIN
  • Stock Information
  • Founded
  • ZLAB 2013
  • TFIN 1981
  • Country
  • ZLAB China
  • TFIN United States
  • Employees
  • ZLAB N/A
  • TFIN N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • TFIN Major Banks
  • Sector
  • ZLAB Health Care
  • TFIN Finance
  • Exchange
  • ZLAB Nasdaq
  • TFIN Nasdaq
  • Market Cap
  • ZLAB 3.6B
  • TFIN 1.3B
  • IPO Year
  • ZLAB 2017
  • TFIN N/A
  • Fundamental
  • Price
  • ZLAB $35.17
  • TFIN $61.52
  • Analyst Decision
  • ZLAB Buy
  • TFIN Hold
  • Analyst Count
  • ZLAB 5
  • TFIN 6
  • Target Price
  • ZLAB $54.28
  • TFIN $68.50
  • AVG Volume (30 Days)
  • ZLAB 987.9K
  • TFIN 212.1K
  • Earning Date
  • ZLAB 08-05-2025
  • TFIN 07-16-2025
  • Dividend Yield
  • ZLAB N/A
  • TFIN N/A
  • EPS Growth
  • ZLAB N/A
  • TFIN N/A
  • EPS
  • ZLAB N/A
  • TFIN 0.37
  • Revenue
  • ZLAB $418,326,000.00
  • TFIN $401,390,000.00
  • Revenue This Year
  • ZLAB $44.07
  • TFIN $12.09
  • Revenue Next Year
  • ZLAB $49.13
  • TFIN $14.37
  • P/E Ratio
  • ZLAB N/A
  • TFIN $164.12
  • Revenue Growth
  • ZLAB 43.72
  • TFIN 0.68
  • 52 Week Low
  • ZLAB $16.01
  • TFIN $42.90
  • 52 Week High
  • ZLAB $44.34
  • TFIN $110.58
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 48.52
  • TFIN 44.42
  • Support Level
  • ZLAB $34.55
  • TFIN $56.05
  • Resistance Level
  • ZLAB $36.73
  • TFIN $57.76
  • Average True Range (ATR)
  • ZLAB 1.35
  • TFIN 1.80
  • MACD
  • ZLAB -0.61
  • TFIN -0.22
  • Stochastic Oscillator
  • ZLAB 7.35
  • TFIN 29.44

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

About TFIN Triumph Financial Inc.

Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.

Share on Social Networks: